<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2651">
  <stage>Registered</stage>
  <submitdate>26/01/2010</submitdate>
  <approvaldate>26/01/2010</approvaldate>
  <nctid>NCT01058434</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation</studytitle>
    <scientifictitle>A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-012417-22</secondaryid>
    <secondaryid>CTKI258A2204</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed or Refractory Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TKI258

Experimental: TKI258 - 


Treatment: drugs: TKI258


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>frequency and severity of adverse events as per CTCAE</outcome>
      <timepoint>throughtout the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival (PFS)</outcome>
      <timepoint>every 4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma exposure of TKI258</outcome>
      <timepoint>during the first 3 cycles</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Cytopathologically or histologically confirmed diagnosis of multiple myeloma
             previously requiring systemic treatment.

          2. Evidence of relapsed or refractory disease as documented from the prior treatment
             history. (Refractory myeloma is defined as disease that is non-responsive while on
             salvage therapy, or progresses within 60 days of last therapy. Relapsed myeloma is
             defined as previously treated myeloma which after a period of being off-therapy
             requires the initiation of salvage therapy. Detailed definitions provided in the
             PTS-1)

          3. Have received at least 2 prior treatment regimens for multiple myeloma including
             chemotherapy, autologous transplantation, immunotherapy, or other investigational
             agents. Pre-planned induction, followed by transplant and maintenance should be
             considered as one regimen.

          4. Presence of measurable disease as defined by at least one of the following;

               -  Serum M-protein = 1g/dL (measurable disease)

               -  Urine M-protein = 200mg/24 hours by protein electrophoresis (measurable disease)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with non-secretory, or oligosecretory, multiple myeloma.

          2. Patients with symptomatic amyloidosis, or with plasma cell leukemia.

          3. Patients who have received allogeneic stem cell transplantation and who show evidence
             of active graft-versus-host disease that requires immunosuppressive therapy.

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>43</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <hospital>Novartis Investigative Site - Melbourne</hospital>
    <hospital>Novartis Investigative Site - Prahran</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - Melbourne</postcode>
    <postcode>3181 - Prahran</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>KÃ¶ln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Altunizade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate safety and efficacy of TKI258 in patients with relapsed or
      refractory multiple myeloma</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01058434</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>